EP2655663A4 - Biomarqueurs et leurs utilisations dans le pronostic et les stratégies de traitement du cancer du côlon droit et du cancer du côlon gauche - Google Patents
Biomarqueurs et leurs utilisations dans le pronostic et les stratégies de traitement du cancer du côlon droit et du cancer du côlon gaucheInfo
- Publication number
- EP2655663A4 EP2655663A4 EP11850360.6A EP11850360A EP2655663A4 EP 2655663 A4 EP2655663 A4 EP 2655663A4 EP 11850360 A EP11850360 A EP 11850360A EP 2655663 A4 EP2655663 A4 EP 2655663A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancer
- biomarkers
- prognosis
- strategies
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
- C12Y106/03—Oxidoreductases acting on NADH or NADPH (1.6) with oxygen as acceptor (1.6.3)
- C12Y106/03001—NAD(P)H oxidase (1.6.3.1), i.e. NOX1
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061459864P | 2010-12-20 | 2010-12-20 | |
| PCT/US2011/066233 WO2012088146A2 (fr) | 2010-12-20 | 2011-12-20 | Biomarqueurs et leurs utilisations dans le pronostic et les stratégies de traitement du cancer du côlon droit et du cancer du côlon gauche |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2655663A2 EP2655663A2 (fr) | 2013-10-30 |
| EP2655663A4 true EP2655663A4 (fr) | 2015-01-28 |
Family
ID=46314850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP11850360.6A Withdrawn EP2655663A4 (fr) | 2010-12-20 | 2011-12-20 | Biomarqueurs et leurs utilisations dans le pronostic et les stratégies de traitement du cancer du côlon droit et du cancer du côlon gauche |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP2655663A4 (fr) |
| WO (1) | WO2012088146A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2821507A1 (fr) * | 2013-07-01 | 2015-01-07 | Centre National de la Recherche Scientifique (CNRS) | Procédé pour détecter, identifier et/ou quantifier un pathogène dans un individu |
| CN114540499A (zh) * | 2022-03-17 | 2022-05-27 | 郑州源创吉因实业有限公司 | 基于pcd相关基因组合构建的模型在制备预测结肠腺癌预后产品中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1355149A2 (fr) * | 2002-03-29 | 2003-10-22 | Ortho-Clinical Diagnostics, Inc. | Procédé de diagnostic du cancer colorectal |
| WO2005010486A2 (fr) * | 2003-07-18 | 2005-02-03 | Lee Nancy M | Groupe special de marquers biologiques pour cancer colorectal |
| WO2010132817A1 (fr) * | 2009-05-14 | 2010-11-18 | Cancer Prevention Pharmaceuticals, Llc | Diagnostic et traitements du carcinome sur la base du génotype odc1 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2919061B1 (fr) * | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal. |
-
2011
- 2011-12-20 WO PCT/US2011/066233 patent/WO2012088146A2/fr not_active Ceased
- 2011-12-20 EP EP11850360.6A patent/EP2655663A4/fr not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1355149A2 (fr) * | 2002-03-29 | 2003-10-22 | Ortho-Clinical Diagnostics, Inc. | Procédé de diagnostic du cancer colorectal |
| WO2005010486A2 (fr) * | 2003-07-18 | 2005-02-03 | Lee Nancy M | Groupe special de marquers biologiques pour cancer colorectal |
| WO2010132817A1 (fr) * | 2009-05-14 | 2010-11-18 | Cancer Prevention Pharmaceuticals, Llc | Diagnostic et traitements du carcinome sur la base du génotype odc1 |
Non-Patent Citations (2)
| Title |
|---|
| See also references of WO2012088146A2 * |
| VINCENT JAQUET ET AL: "FORUM REVIEW ARTICLE Small-Molecule NOX Inhibitors: ROS-Generating NADPH Oxidases as Therapeutic Targets Introduction: NOX Enzymes and Their Distribution/Regulation", ANTIOXIDANTS AND REDOX SIGNALING, 1 October 2009 (2009-10-01), pages 2535 - 2552, XP055212413, Retrieved from the Internet <URL:http://online.liebertpub.com/doi/pdf/10.1089/ars.2009.2585> [retrieved on 20150910] * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012088146A2 (fr) | 2012-06-28 |
| WO2012088146A3 (fr) | 2012-10-11 |
| EP2655663A2 (fr) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3296319T3 (pl) | Sposoby leczenia nowotworu jelita grubego | |
| EP2603622A4 (fr) | Biomarqueurs du cancer du pancréas et leurs utilisations | |
| EP2872144A4 (fr) | Inhibiteurs d'irak et leurs utilisations | |
| SI2619576T1 (sl) | Sredstva in metode za predvidevanje odziva rakavega pacienta na zdravljenje | |
| EP2756093A4 (fr) | Anticorps de c10rf32 et leurs utilisations pour traiter le cancer | |
| EP2771692A4 (fr) | Biomarqueurs de cancer du poumon et leurs utilisations | |
| DK2868102T3 (da) | Tiles og wavefront front parallel processering | |
| EP2744830A4 (fr) | Anticorps anti-lsr et leurs utilisations pour le traitement du cancer | |
| EP2972308A4 (fr) | Biomarqueurs et procédés de prédiction d'une naissance prématurée | |
| BR112014007603A2 (pt) | métodos de tratamento do câncer | |
| EP2938459A4 (fr) | Matières particulaires et leurs procédés de formation | |
| EP2925888A4 (fr) | Compositions et procédés pour traiter le cancer | |
| EP2575804A4 (fr) | Procédés de traitement du cancer du pancréas | |
| LT2707030T (lt) | Vėžio gydymas | |
| EP2805167A4 (fr) | Biomarqueurs pour le cancer gastrique et leurs utilisations | |
| PL2550294T3 (pl) | Profilaktyka nowotworu jelita grubego i nowotworu przewodu pokarmowego | |
| HRP20181462T1 (hr) | Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva | |
| HRP20181576T8 (hr) | Blok za dijagnosticiranje transakcije | |
| BR112012002571A2 (pt) | tratamento de minérios de titânio | |
| EP2672970A4 (fr) | Formes de rifaximine et leurs utilisations | |
| EP2714023A4 (fr) | Nano-ensembles polymères réticulés et leurs utilisations | |
| BR112013011659A2 (pt) | métodos de tratamento do câncer | |
| BR112014011008A2 (pt) | método de quantificação de tratamento de câncer | |
| EP2903605A4 (fr) | Angiotensine dans le traitement d'états cérébraux | |
| PL2742356T3 (pl) | Środki prognostyczne w leczeniu nowotworów |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20130722 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20150107 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/574 20060101ALI20141219BHEP Ipc: C12N 15/113 20100101ALI20141219BHEP Ipc: C12N 15/11 20060101ALI20141219BHEP Ipc: C12Q 1/68 20060101AFI20141219BHEP |
|
| 17Q | First examination report despatched |
Effective date: 20150915 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20190103 |